Drug Trial Radar · NCT03774056
A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.
Last checked: Nov 20, 2026Latest source record: Nov 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Feb 10, 2017
Primary completion
Sep 26, 2018
Study completion Aug 28, 2019
Sponsor
- Lead sponsor
- Hinova Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- Collaborators
- West China Hospital
- First posted
- Dec 12, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I study evaluating tolerability, pharmacokinetics, and preliminary efficacy of HC-1119 in patients with metastatic castration-resistant prostate cancer. The study objective is to study the tolerability, safety, and dose-limiting toxicities (DLT) of HC-1119 in patients with mCRPC.
Conditions
- Metastatic Castration Resistant Prostate Cancer
Interventions
HC-1119Drug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicities(DLT)Time frame: From the first dose of the study to the 12th week after dose
- Number of patients with adverse eventsTime frame: From the first dose of the study to the 12th week after dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hinova Pharmaceuticals Inc.
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.